159 related articles for article (PubMed ID: 16683063)
41. Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures.
Baulac M; Brodie MJ; Elger CE; Krakow K; Stockis A; Meyvisch P; Falter U
Epilepsia; 2007 Mar; 48(3):589-92. PubMed ID: 17326794
[TBL] [Abstract][Full Text] [Related]
42. Levetiracetam extended release for the treatment of patients with partial-onset seizures: A long-term, open-label follow-up study.
Chung S; Ceja H; Gawłowicz J; McShea C; Schiemann J; Lu S
Epilepsy Res; 2016 Feb; 120():7-12. PubMed ID: 26716580
[TBL] [Abstract][Full Text] [Related]
43. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study.
Lim DA; Tarapore P; Chang E; Burt M; Chakalian L; Barbaro N; Chang S; Lamborn KR; McDermott MW
J Neurooncol; 2009 Jul; 93(3):349-54. PubMed ID: 19169651
[TBL] [Abstract][Full Text] [Related]
44. Levetiracetam in clinical practice: efficacy and tolerability in epilepsy.
Bilo L; de Leva MF; Meo R
Can J Neurol Sci; 2010 May; 37(3):376-82. PubMed ID: 20481273
[TBL] [Abstract][Full Text] [Related]
45. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study.
Delanty N; Jones J; Tonner F
Epilepsia; 2012 Jan; 53(1):111-9. PubMed ID: 22050371
[TBL] [Abstract][Full Text] [Related]
46. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations.
Magaudda A; Gelisse P; Genton P
Epilepsia; 2004 Jun; 45(6):678-81. PubMed ID: 15144434
[TBL] [Abstract][Full Text] [Related]
47. Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam.
Cramer JA; Van Hammée G;
Epilepsy Behav; 2003 Apr; 4(2):118-23. PubMed ID: 12697135
[TBL] [Abstract][Full Text] [Related]
48. Long-term levetiracetam treatment of epilepsy patients: clinical audit.
Kuba R; Novotná I; Brázdil M; Kocvarová J; Tyrliková I; Mastík J; Rektor I
Epilepsy Res; 2006 Dec; 72(2-3):111-9. PubMed ID: 16930945
[TBL] [Abstract][Full Text] [Related]
49. Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA).
Stefan H; Wang-Tilz Y; Pauli E; Dennhöfer S; Genow A; Kerling F; Lorber B; Fraunberger B; Halboni P; Koebnick C; Gefeller O; Tilz C
Epilepsia; 2006 Mar; 47(3):516-22. PubMed ID: 16529615
[TBL] [Abstract][Full Text] [Related]
50. Levetiracetam monotherapy for children and adolescents with benign rolandic seizures.
Verrotti A; Coppola G; Manco R; Ciambra G; Iannetti P; Grosso S; Balestri P; Franzoni E; Chiarelli F
Seizure; 2007 Apr; 16(3):271-5. PubMed ID: 17204435
[TBL] [Abstract][Full Text] [Related]
51. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
[TBL] [Abstract][Full Text] [Related]
52. Levetiracetam in patients with central neuropathic post-stroke pain--a randomized, double-blind, placebo-controlled trial.
Jungehulsing GJ; Israel H; Safar N; Taskin B; Nolte CH; Brunecker P; Wernecke KD; Villringer A
Eur J Neurol; 2013 Feb; 20(2):331-7. PubMed ID: 22925226
[TBL] [Abstract][Full Text] [Related]
53. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy.
Ben-Menachem E; Edrich P; Van Vleymen B; Sander JW; Schmidt B
Epilepsy Res; 2003 Feb; 53(1-2):57-64. PubMed ID: 12576168
[TBL] [Abstract][Full Text] [Related]
54. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.
Betts T; Waegemans T; Crawford P
Seizure; 2000 Mar; 9(2):80-7. PubMed ID: 10845730
[TBL] [Abstract][Full Text] [Related]
55. Levetiracetam for people with mental retardation and refractory epilepsy.
Kelly K; Stephen LJ; Brodie MJ
Epilepsy Behav; 2004 Dec; 5(6):878-83. PubMed ID: 15582836
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures.
Xiao Z; Li JM; Wang XF; Xiao F; Xi ZQ; Lv Y; Sun HB
Eur Neurol; 2009; 61(4):233-9. PubMed ID: 19176965
[TBL] [Abstract][Full Text] [Related]
57. Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group.
Cramer JA; Arrigo C; Van Hammée G; Gauer LJ; Cereghino JJ
Epilepsia; 2000 Jul; 41(7):868-74. PubMed ID: 10897159
[TBL] [Abstract][Full Text] [Related]
58. Levetiracetam in stiff-person syndrome.
Sechi G; Barrocu M; Piluzza MG; Cocco GA; Deiana GA; Sau GF
J Neurol; 2008 Nov; 255(11):1721-5. PubMed ID: 18769864
[TBL] [Abstract][Full Text] [Related]
59. Intravenous levetiracetam treatment in status epilepticus: A prospective study.
Atmaca MM; Orhan EK; Bebek N; Gurses C
Epilepsy Res; 2015 Aug; 114():13-22. PubMed ID: 26088881
[TBL] [Abstract][Full Text] [Related]
60. Intravenous levetiracetam in clinical practice--Results from an independent registry.
Lang N; Esser W; Evers S; Kellinghaus C; Nguento A; Schlegel U; Gaida B; Gburek-Augustat J; Altenmüller DM; Burghaus L; Hoffmann F; Fiedler B; Bast T; Rehfeld T; Happe S; Seitz RJ; Boor R; Stephani U
Seizure; 2015 Jul; 29():109-13. PubMed ID: 26076852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
